10-Q: Cryo-Cell International Reports Q1 2025 Results Amidst Legal Dispute with Duke University

Cryo-Cell International's Q1 2025 revenue increased slightly, but the company faces ongoing legal challenges and uncertainties regarding its Duke University license agreement.

Summary

• Cryo-Cell International, Inc. reported a net income of $282,855 for the three months ended February 28, 2025, compared to $556,241 for the same period in 2024.
• Total revenue increased by 2% to $7,968,880, driven by a rise in processing and storage fees and public banking revenue.
• The company is currently involved in an arbitration demand against Duke University, alleging fraudulent inducement and breach of contract related to a license agreement.
• As of April 14, 2025, 8,082,159 shares of common stock were outstanding.
• The company declared a cash dividend of $0.25 per share, paid on February 28, 2025, totaling $2,020,539.
• The company's cash and cash equivalents decreased to $223,122 from $560,960 at the beginning of the period.
• The company has a revolving line of credit with a balance of $4,570,000 as of February 28, 2025.
• The company is amortizing costs associated with the Duke License Agreement over 16 years, but has recorded an impairment charge of $13,108,064 during fiscal 2023.
• The company is organized into three reportable segments: umbilical cord blood and cord tissue stem cell service, PrepaCyte CB, and public cord blood banking.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased slightly, the decrease in net income, the ongoing legal dispute with Duke University, and the uncertainty surrounding future plans create a mixed outlook.

Positives

• Revenue increased by 2% compared to the same period last year.
• Processing and storage fees saw an increase, indicating continued demand for core services.
• Public cord blood banking revenue increased from $43,713 to $82,079.
• The company is actively pursuing legal action against Duke University, potentially recovering significant damages.

Negatives

• Net income decreased from $556,241 to $282,855 compared to the same period last year.
• Cash and cash equivalents decreased significantly.
• The company recorded an impairment charge of $13,108,064 related to the Duke License Agreement during fiscal 2023.
• The company is involved in ongoing legal proceedings, creating uncertainty and potential financial burden.

Risks

• The ongoing arbitration demand against Duke University poses a significant risk, with uncertain outcomes and potential material impacts on the company's financial position.
• The company's ability to expand its business into biopharmaceutical manufacturing and operating clinics is uncertain due to the Duke dispute.
• The company may need to raise additional capital, but there is no assurance that it will be able to obtain financing on favorable terms.
• The company faces increasing competition in the stem cell preservation market.
• The company's operations are vulnerable to damage or interruption from various events, including fire, flood, and equipment failure.
• The company's future success depends on its ability to retain key personnel and attract qualified employees.
• The company is subject to substantial government regulation, and failure to comply with these regulations could result in penalties and restrictions.
• The company's international operations are subject to various risks, including failure of local laws to protect intellectual property rights and fluctuations in currency exchange rates.

Future Outlook

The company anticipates that its cash and cash equivalents, marketable securities, and cash flows from operations, together with external sources of capital, will be sufficient to fund its known cash needs for at least the next 12 months, but the outcome of the Duke Arbitration Demand creates uncertainty.

Management Comments

• The company is actively pursuing legal action against Duke University to recover damages and protect its interests.
• The company is managing discretionary expenses to ensure sufficient cash resources.
• The company is focused on increasing revenues from sales of its umbilical cord blood and cord tissue cellular storage services.

Industry Context

The stem cell preservation market is becoming increasingly competitive, with new entrants and evolving technologies. Cryo-Cell International faces competition from other operators of stem cell preservation businesses and providers of stem storage services.

Comparison to Industry Standards

• It is difficult to compare Cryo-Cell's results directly to industry standards due to the limited number of publicly traded, pure-play cord blood banking companies.
• Comparable companies include ViaCord (owned by PerkinElmer) and CBR (Cord Blood Registry), but these are either privately held or part of larger entities, making direct financial comparisons challenging.
• Industry benchmarks often focus on metrics like cord blood unit collection rates, storage volumes, and transplant outcomes, which are not fully detailed in this report.
• The company's AABB and FACT accreditations are positive indicators of quality and adherence to industry standards.
• The company's ongoing legal dispute with Duke University is a unique situation that does not have a direct industry comparison.

Legal Proceedings

• The company is involved in an arbitration demand against Duke University, alleging fraudulent inducement and breach of contract related to a license agreement.
• The company is contesting a claim filed in the Circuit Court for Palm Beach County, Florida, alleging inaccurate advertising.

Stakeholder Impact

• Shareholders are impacted by the decrease in net income and the uncertainty surrounding the Duke University dispute.
• Employees may be affected by potential cost-cutting measures or changes in business strategy.
• Customers may be impacted by any disruptions to services or changes in the company's offerings.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to pursue its arbitration demand against Duke University.
• The company will manage its cash resources and discretionary expenses.
• The company will monitor the stem cell preservation market and adapt to changing industry conditions.

Key Dates

Keywords

Cryo-Cell International, cord blood, stem cells, Duke University, arbitration, revenue, financial results, legal proceedings, license agreement, PrepaCyte CB, public banking, cryopreservation